Title: Aclidinium bromide for the treatment of chronic obstructive pulmonary disease.
Journal: Expert opinion on pharmacotherapy 20130601
Title: Aclidinium bromide twice daily for the treatment of chronic obstructive pulmonary disease: a review.
Journal: Advances in therapy 20130401
Title: Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study.
Journal: The European respiratory journal 20121001
Title: Aclidinium bromide oral inhalation powder approved for COPD.
Journal: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20120901
Title: A randomised, placebo- and active-controlled dose-finding study of aclidinium bromide administered twice a day in COPD patients.
Journal: Pulmonary pharmacology & therapeutics 20120601
Title: Pharmacokinetics and safety of aclidinium bromide in younger and elderly patients with chronic obstructive pulmonary disease.
Journal: International journal of clinical pharmacology and therapeutics 20120601
Title: Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I).
Journal: COPD 20120401
Title: Safety and pharmacokinetics of multiple doses of aclidinium bromide administered twice daily in healthy volunteers.
Journal: Pulmonary pharmacology & therapeutics 20120401
Title: Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD.
Journal: Chest 20120301
Title: Aclidinium inhibits human lung fibroblast to myofibroblast transition.
Journal: Thorax 20120301
Title: The Genuair® inhaler: a novel, multidose dry powder inhaler.
Journal: International journal of clinical practice 20120301
Title: Aclidinium bromide, a novel long-acting muscarinic antagonist for COPD with improved preclinical renal and urinary safety profile.
Journal: Life sciences 20120213
Title: Mass balance and metabolism of aclidinium bromide following intravenous administration of [¹⁴C]-aclidinium bromide in healthy subjects.
Journal: Biopharmaceutics & drug disposition 20120101
Title: Inhalation by design: novel tertiary amine muscarinic M₃ receptor antagonists with slow off-rate binding kinetics for inhaled once-daily treatment of chronic obstructive pulmonary disease.
Journal: Journal of medicinal chemistry 20111013
Title: Aclidinium bromide, a long-acting antimuscarinic, does not affect QT interval in healthy subjects.
Journal: Journal of clinical pharmacology 20110601
Title: Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD.
Journal: Respiratory medicine 20110401
Title: In vitro liver metabolism of aclidinium bromide in preclinical animal species and humans: identification of the human enzymes involved in its oxidative metabolism.
Journal: Biochemical pharmacology 20110315
Title: Aclidinium inhibits cholinergic and tobacco smoke-induced MUC5AC in human airways.
Journal: The European respiratory journal 20110201
Title: An update on the efficacy and safety of aclidinium bromide in patients with COPD.
Journal: Therapeutic advances in respiratory disease 20110201
Title: Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease.
Journal: Respiratory research 20110101
Title: Profile of aclidinium bromide in the treatment of chronic obstructive pulmonary disease.
Journal: International journal of chronic obstructive pulmonary disease 20110101
Title: Aclidinium bromide abrogates allergen-induced hyperresponsiveness and reduces eosinophilia in murine model of airway inflammation.
Journal: European journal of pharmacology 20101215
Title: The discovery of new spirocyclic muscarinic M3 antagonists.
Journal: Bioorganic & medicinal chemistry letters 20101215
Title: Onset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPD.
Journal: COPD 20101001
Title: Pharmacokinetics and safety of aclidinium bromide, a muscarinic antagonist, in adults with normal or impaired renal function: A phase I, open-label, single-dose clinical trial.
Journal: Clinical therapeutics 20100901
Title: Identification of the human enzymes responsible for the enzymatic hydrolysis of aclidinium bromide.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20100701
Title: Bronchodilatory effects of aclidinium bromide, a long-acting muscarinic antagonist, in COPD patients.
Journal: Respiratory medicine 20100601
Title: Activity of aclidinium bromide, a new long-acting muscarinic antagonist: a phase I study.
Journal: British journal of clinical pharmacology 20100501
Title: Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites.
Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20100318
Title: Aclidinium bromide provides long-acting bronchodilation in patients with COPD.
Journal: Pulmonary pharmacology & therapeutics 20100201
Title: Peak inspiratory flow through the Genuair inhaler in patients with moderate or severe COPD.
Journal: Respiratory medicine 20091201
Title: Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile.
Journal: The Journal of pharmacology and experimental therapeutics 20091101
Title: Safety and pharmacokinetics of multiple doses of aclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease, in healthy participants.
Journal: Journal of clinical pharmacology 20091001
Title: Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinol esters as potent and long-acting muscarinic antagonists with potential for minimal systemic exposure after inhaled administration: identification of (3R)-3-{[hydroxy(di-2-thienyl)acetyl]oxy}-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide (aclidinium bromide).
Journal: Journal of medicinal chemistry 20090827
Title: Safety and pharmacokinetics of single doses of aclidinium bromide, a novel long-acting, inhaled antimuscarinic, in healthy subjects.
Journal: International journal of clinical pharmacology and therapeutics 20090701
Title: Aclidinium bromide, a novel long-acting muscarinic M3 antagonist for the treatment of COPD.
Journal: Current opinion in investigational drugs (London, England : 2000) 20090501
Title: Lung deposition of aclidinium bromide from Genuair, a multidose dry powder inhaler.
Journal: Respiration; international review of thoracic diseases 20090101
Title: Genuair is a good inhaler but an indirect comparison with other dry powder inhalers is inadequate.
Journal: Respiration; international review of thoracic diseases 20090101
Title: Cazzola M. Aclidinium bromide, a novel long-acting muscarinic M3 antagonist for the treatment of COPD. Curr Opin Investig Drugs. 2009 May;10(5):482-90.
Title: Joos GF. Potential for long-acting muscarinic antagonists in chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2010 Feb;19(2):257-64.
Title: Sentellas S, Ramos I, Albertí J et al. Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites. Eur J Pharm Sci. 2010 Mar 18;39(5):283-90.
Title: Sims MW, Panettieri RA Jr. Profile of aclidinium bromide in the treatment of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2011;6:457-66.
